AGÕæÈ˹ٷ½

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, and Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head, Oncology, will participate in a virtual fireside chat at the TD Cowen 6^th Annual Oncology Innovation Summit on Tuesday, May 27 at 1:30 p.m. PT / 4:30 p.m. ET.

A live webcast of the fireside chat will be made available under in the Investors section of the and will be archived for 30 days.

About Vir Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

View source version on businesswire.com:

Media

Corporate Communications, Vir Biotechnology

[email protected]

Investors

Richard Lepke

Senior Director, Investor Relations

[email protected]

Source: Vir Biotechnology, Inc.